Marc Beer is the co-founder of Renovia Inc. alongside Ramon Iglesias and Yolanda Lorie. The Boston based Biotechnology Company has for the past two years been developing different diagnostic and therapeutic treatment products for the treatment of pelvic floor problems. The health disorder that primarily affects women, and also known as urinary incontinence, is estimated to affect over $250 million women in the world.
Barely 24 months after establishment, Renovia had already come up with a diagnosis and treatment for the pelvic floor health problem. A big percentage of the success here is credited to Marc Beer who is a blend of rich experience, expertise in pharmaceuticals helped speed up this process. The company’s first product referred to as Leva was approved by FDA in April for distribution and administration to patients. Renovia is expected to continue creating more products to address this disorder.
Raising $42 million
Recently, Marc Beer raised $42 million to help fund this startup healthcare company advance its research and drug development. The Series B round funding helped raise over $32 million in equity capital and $10 million in form of venture debt. Marc mentioned that these funds will be used in advancing clinical testing and pushing the different products they have in the pipeline towards FDA approval. More importantly, the funds will help speed up the finalization of the development and release of a new version of the Leva drug.
While March Beer did not speak choose not to reveal much about their pipeline products, he expressed his gratitude for the financial support offered by the leading healthcare investors. These include Longwood fund and OSF ventures and their contributions will help come up with better diagnostic tools for effective treatments and improvement of women health.
Marc Beer’s Background
Marc Beer has had close to three decades of experience in the biotechnology and pharmaceutical industry, most of which was spent in the development and commercialization of drugs and medical inventions. Before co-founding Renovia, he had worked with the Michigan-based Milliendo Therapeutics, ViaCell and Abbott Laboratories. He graduated with a Bachelor of Science from Miami University, Ohio.
Marc has had an excellent track record in technology and medicine and rose to prominence in the health industry after founding ViaCell. He helped manage the firm as its Chief executive officer and within two years, it had over 300 employees before going public in 2005. Marc would also play a key role in facilitating its acquisition by Perkin Elmer in 2007.
Beer also worked in various companies in the technology and medical world where he managed different projects including sales and marketing. The positions that he has held in his career were not only related to diagnostics and pharmaceutical products, but they also helped him know what people want and need most. He is using that experience in his work at Renovia Inc. Learn more: https://renoviainc.com/leadership/
Men and women have a pelvic floor. In the latter, the pelvic floor muscles include ligaments, nerves as well as connective tissues that support the bladder. All these tissues help to support the pelvic organ functions. For many, the pelvic floor doesn’t work as required. Almost a quarter of these women suffer pelvic floor disorders, and that’s why Marc Beer, the serving CEO of Renovia has stepped up to help complete the Series B Financing.
Marc Beer Chairs The Series B Funding to Support Women with Pelvic Floor Disorders
Marc Beer has a stellar reputation of changing startups into useful commercial enterprises that have strong financial muscles with the aim of achieving various strategic needs. He recently chaired the Series B Financing which raised about $42 billion for the research and development of urinary incontinence that affects many women. The funds will be used to develop affordable drugs for the same medical condition. Through Marc Beer, the funds were raised via an infusion that propelled the company towards receiving various funds from investment firms such as Ascension Ventures and Longwood Fund. The same funds will also be used in developing Revia which awaits the FDA approval. The new round of financing will assist the company to perfect their diagnostic systems for pelvic floor disorders by merging innovative technologies with value-added digital platforms. The merger will lead to reduced costs of treating pelvic floor disorders in women.
Marc Beer is a Great Business Originator
Marc Beer is a committed business professional with the unmatched commitment of transforming emerging businesses into profitable commercial enterprises. He then founded Revia Inc. Through his exemplary leadership, he’s been guiding the company towards initiating useful funding as well as the development of an FDA approved drug. The specialists will provide a broad range of diagnostic services to care for the sensitive matter. Over the years, Marc Beer has successfully founded various firms including ViaCell where he serves as the CEO. The company capitalizes on stem cell research. Under his leadership, the company received recognition from the NASQAD while its worker base tremendously grew within the few years of its founding. The move attracted big corporations such as PerkinElmer. After the acquisition of ViaCell, Marc Beer joined Erytech Pharma where he served as the board member. He additionally founded Good Start Genetics and served as the head of operations.
Marc Beer’s Professional Background and Experience
Marc Beer is a revered business developer with extensive experience in the pharmaceutical industry. He also doubles as a sales and marketing personnel. Prior to venturing in the startup industry, he served a vice president at Genzyme and oversaw the marketing unit. He is a holder of a bachelor’s degree in science and business studies. Learn more: https://renoviainc.com/